Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice
Pathogens · 2024
DOI: 10.3390/pathogens13020097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Erika Petro-Turnquist und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA. Hauptthemen laut MEDLINE: Influenza B virus, Influenza Vaccines, Orthomyxoviridae Infections, Antibodies, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health (NIH) under Ruth L. Kirschstein National Research Service Award.
Abstract (Originalsprache)
Influenza B virus is a respiratory pathogen that contributes to seasonal epidemics, accounts for approximately 25% of global influenza infections, and can induce severe disease in young children. While vaccination is the most commonly used method of preventing influenza infections, current vaccines only induce strain-specific responses and have suboptimal efficacy when mismatched from circulating strains. Further, two influenza B virus lineages have been described, B/Yamagata-like and B/Victoria-like, and the limited cross-reactivity between the two lineages provides an additional barrier in developing a universal influenza B virus vaccine. Here, we report a novel multivalent vaccine using computationally designed Epigraph hemagglutinin proteins targeting both the B/Yamagata-like and B/Victoria-like lineages. When compared to the quadrivalent commercial vaccine, the Epigraph vaccine demonstrated increased breadth of neutralizing antibody and T cell responses. After lethal heterologous influenza B virus challenge, mice immunized with the Epigraph vaccine were completely protected against both weight loss and mortality. The superior cross-reactive immunity conferred by the Epigraph vaccine immunogens supports their continued investigation as a universal influenza B virus vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
- Science Department, North Arkansas College, Harrison, AR 72601, USA.
- College of Agricultural Sciences and Natural Resources, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
ORCID-Profile: Erika Petro-Turnquist, Matthew J Pekarek, Eric A Weaver
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health (NIH) under Ruth L. Kirschstein National Research Service Award
- the NIH, National Institute for Allergies and Infectious Diseases (NIAID)
Zitieren
APA
Petro-Turnquist, E., Corder Kampfe, B., Gadeken, A., Pekarek, M. J., & Weaver, E. A. (2024). Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice. Pathogens. https://doi.org/10.3390/pathogens13020097
Vancouver
Petro-Turnquist E, Corder Kampfe B, Gadeken A, Pekarek MJ, Weaver EA. Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice. Pathogens. 2024. doi:10.3390/pathogens13020097
BibTeX
@article{PetroTurnquist2024,
author = {Petro-Turnquist, Erika and Corder Kampfe, Brigette and Gadeken, Amber and Pekarek, Matthew J and Weaver, Eric A},
title = {Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13020097}
}
EUVIMED